Reuven Reich
- Immunology and Allergy top 0.2%
- Cell Adhesion Molecules Research 30
- Cancer Research top 0.2%
- Protease and Inhibitor Mechanisms 46
- MicroRNA in disease regulation 11
- Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment 12
- Oncology top 0.5%
- Peptidase Inhibition and Analysis 36
- Hematology top 1%
- Blood Coagulation and Thrombosis Mechanisms 15
-
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 15
-
- Angiogenesis and VEGF in Cancer 11
Reuven Reich
200 papers receiving 10.9k citations
Peers
Comparison fields: 5 of 136
- Immunology and Allergy 1.4k
- Cancer Research 3.4k
- Reproductive Medicine 1.1k
- Oncology 3.0k
- Hematology 993
Countries citing papers authored by Reuven Reich
This map shows the geographic impact of Reuven Reich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reuven Reich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reuven Reich more than expected).
Fields of papers citing papers by Reuven Reich
This network shows the impact of papers produced by Reuven Reich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reuven Reich. The network helps show where Reuven Reich may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Reuven Reich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2020 | 3 | |
| 3 | 2019 | 29 | |
| 4 | 2013 | 28 | |
| 5 | 2012 | 15 | |
| 6 | 2011 | 11 | |
| 7 | 2010 | 17 | |
| 8 | 2008 | 38 | |
| 9 | 2008 | 23 | |
| 10 | 2006 | 35 | |
| 11 | 2006 | 25 | |
| 12 | 2005 | 84 | |
| 13 | 2005 | 22 | |
| 14 | 1999 | 167 | |
| 15 | 1999 | 54 | |
| 16 | 1999 | 98 | |
| 17 | 1995 | 28 | |
| 18 | 1990 | 39 | |
| 19 | 1989 | 86 | |
| 20 | Use of a reconstituted basement-membrane to study the invasiveness of tumor-cells | 1987 | 1 |
About Reuven Reich
Reuven Reich is a scholar working on Immunology and Allergy, Cancer Research and Reproductive Medicine, having authored 202 papers that have together received 11.2k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (46 papers), Peptidase Inhibition and Analysis (36 papers), Cell Adhesion Molecules Research (30 papers), Blood Coagulation and Thrombosis Mechanisms (15 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (15 papers), Ovarian cancer diagnosis and treatment (12 papers), MicroRNA in disease regulation (11 papers) and Angiogenesis and VEGF in Cancer (11 papers). The work is most often cited by research in Immunology and Allergy (1.4k citations), Cancer Research (3.4k citations) and Reproductive Medicine (1.1k citations). Reuven Reich has collaborated with scholars based in Israel, Norway and United States. Frequent co-authors include Ben Davidson, Claes G. Tropé, A. Tsafriri, Iris Goldberg, Jahn M. Nesland, Claes G. Tropé, Vered Givant-Horwitz, Menashe Bar‐Eli, Ruth Miskin and Juri Kopolovic. Their work appears in journals such as Gynecologic Oncology, Human Pathology, Clinical & Experimental Metastasis, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.